Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
191
resultados
Última actualización
30/09/2025 [06:51:00]
Resultados 50 a 75 de 191
Resumen de: CN119768157A
The present invention relates to a kit for preparing nanoparticles containing a drug and a nanoparticle composition for delivering a drug, and more particularly, to a kit for preparing nanoparticles containing a drug and a nanoparticle composition for delivering a drug, the kit is designed to increase the cellular delivery efficiency of a drug by using nanoparticles comprising a cationic compound and an anionic polymer compound having at least one acidic functional group.
Resumen de: MX2025002804A
A sheet for radiotherapy, which includes a sheet base configured for placement on tissue of a patient and a radium-binding material coupled to the base sheet. Alpha-emitting radium radionuclides are coupled to the radium-binding material. The radium radionuclides do not leave the sheet, but radon and lead resulting from decay of the radium radionuclides easily leave the sheet.
Resumen de: WO2024054901A1
The present invention relates to novel piperazine compounds, in particular, of formula (I) or formula (II). These piperazine compounds can be used, for example, in lipid nanoparticle compositions for drug delivery and cancer treatments.
Resumen de: MX2025002927A
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.
Resumen de: WO2025198537A1
The present invention provides methods for enhancing cellular binding or entry of a peptide coacervate composition utilising a peptide that comprises a cholesterol binding domain/motif. The invention also covers novel peptide coacervates that comprise a peptide that comprises a cholesterol binding domain/motif, optionally peptide coacervates that also comprises a payload, such as an active agent to be delivered into the cell, and their use in therapy or diagnosis.
Resumen de: WO2025199302A1
A pH-sensitive cationic lipid, a lipid nanoparticle including the pH-sensitive lipid, and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject. The lipid nanoparticle may include a compound represented by general formula (I) or pharmaceutically acceptable salt thereof: (R1)(R2)C(OH) -(CH2)a-(O-CO)b-X (I) wherein a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A): (R11)(R12) - CH-(CH2)w - (CO-O)c - (CH2)v - (A), wherein R11 and R12 each independently represent C5-15 alkoxy group; each c independently represents 0 or 1; each v independently represents an integer of 4-12; each w independently represents an integer of 0-3; and X represents a 5- to 7-membered non-aromatic heterocyclic group, wherein a carbon atom of the heterocyclic group is bound to (O-CO)b- and one or two hydrogen atoms of the heterocyclic group may optionally be replaced with C1-4 alkyl group or C2-4 alkenyl group.
Resumen de: JP2025024198A
To provide nucleic acid based compounds or polynucleotides having features which are useful for optimizing formulation and delivery of nucleic acid based therapeutics.SOLUTION: An isolated polynucleotide comprises: (a) a first region of linked nucleosides, the first region encoding a polypeptide of interest, the polypeptide of interest having prescribed sequences; (b) a first flanking region located at a 5' terminus of the first region, the first flanking region comprising (i) a sequence of linked nucleosides selected from a native 5' UTR and (ii) at least one 5' terminal cap; and (c) a second flanking region located at a 3' terminus of the first region, the second flanking region comprising (i') a sequence of linked nucleosides selected from a native 3' UTR and (ii') a 3' tailing sequence of linked nucleosides.SELECTED DRAWING: Figure 1
Resumen de: WO2025198369A1
The present invention relates to a novel provitamin B5-based lipid derivative compound, a lipid nanoparticle composition comprising same, and the like. More specifically, the novel provitamin B5-based lipid compound functions as an ionizable lipid in the formation of lipid nanoparticles and forms stable lipid nanoparticles, which can be used for delivering pharmaceutically active ingredients such as mRNA into the body.
Resumen de: WO2025197935A1
The present invention provides a drug-polymer complex that includes a drug and a drug delivery polymer having a phosphocholine group, and that exhibits a dissociation constant (KD) of 1.0×10-6M or less with respect to STARD7.
Resumen de: WO2025198324A1
The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.
Resumen de: WO2025196687A1
According to an aspect of the present disclosure, a composition for use in inhibiting viability of triple negative breast cancer (TNBC) cells contains 1,8-cineole as an active ingredient and β-cyclodextrin as a carrier, where the β-cyclodextrin encapsulates the 1,8-cineole forming a nanoformulation. According to another aspect of the present disclosure, a method of preparing a composition for use in inhibiting viability of TNBC cells includes forming a first solution by dissolving β-cyclodextrin in a solvent, forming a second solution by adding Elettaria cardamomum essential oil to the first solution, where the Elettaria cardamomum essential oil contains 1,8-cineole as an active ingredient. The method also includes sonicating the second solution to form a homogenized second solution, centrifuging the homogenized second solution to form a pellet, deep freezing the pellet, and lyophilizing the deep frozen pellet to form a nanoformulation, where the nanoformulation contains the 1,8-cineole encapsulated by the β-cyclodextrin.
Resumen de: WO2025196641A1
The invention relates to the field of medicine, and more particularly to bioengineering, genetic engineering, gene editing, molecular medicine, nanotechnology, biotechnology, nanoengineering and protein engineering. The invention can be used for packaging any RNA, DNA, or a mixture thereof into biological nanoparticles of any origin and composition, inter alia nanoparticles enriched with a protein of interest.
Resumen de: WO2025196660A1
The present disclosure provides nanoparticles having RGD-based peptides conjugated thereto. The nanoparticles may be formed one or more covalent organic frameworks (COFs) of the present disclosure. Also disclosed are methods of making the COFs and nanoparticles. The COFs have one or more binding partners and/or COF (following conjugation of the binding partner) may have an RGD-based peptide. The RGD- based peptide may be selected based on the desire to treat a specific cancer. COFs may have the following structure: Formula (I), where L is a linker group and Peptide is an RGD-based peptide.
Resumen de: WO2025195308A1
The present application provides new cationic lipid compounds and a composition containing the compounds. A nanoparticle composition contains new cationic lipid compounds and other lipids, such as phospholipids, structural lipids and PEG lipids. Additionally, the nanoparticle composition of the present application can be used to deliver a therapeutic agent and/or a prophylactic agent to mammalian cells or organs to, for example, regulate polypeptide, protein or gene expression.
Resumen de: WO2025195465A1
Provided is use of a magnetoelectrically driven magnetostrictive piezoelectric nanoparticle in antiviral therapy. The magnetostrictive piezoelectric nanoparticle comprises a shell structure with piezoelectric properties and a core structure with magnetoelectric response properties. The magnetostrictive piezoelectric nanoparticle, by means of up-regulating multiple immunomodulatory pathways, effectively enhances the expression of type I interferon and a host's innate immune response, ultimately inhibiting the viral activity, ameliorating hepatic and pulmonary tissue damage, and improving the survival rates. The magnetostrictive piezoelectric nanoparticle has the advantages such as high controllability, deep penetration, and non-invasiveness, and offers broad application prospects in the antiviral field.
Resumen de: WO2025194234A1
The present invention relates to a method for preparing nano-structured lipid carriers that are nanometric systems compatible with hydrophobic drug products and that do not exhibit toxicity due to their excipients. These nano-structured lipid carriers contain co-encapsulated cannabidiol and paclitaxel and have applications in the pharmaceutical field, more specifically in antitumour therapy.
Resumen de: WO2025194409A1
The present disclosure relates to novel lipids for delivering one or more biologically active molecules to a subject. The present application also relates to a composition or a nanoparticle comprising said lipid, methods of preparing said lipid, use of said lipid and method of using said lipid.
Resumen de: GB2639326A
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
Resumen de: WO2024108173A1
A nanoparticle and methods of using the same wherein the nanoparticle includes a prodrug comprising a targeting moiety-lipid conjugate, a polyethylene glycol-lipid conjugate, a sterol, a bulk lipid, and a drug-lipid conjugate, wherein a chemical linker group is positioned between the drug moiety and the lipid moiety of the drug-lipid conjugate. The nanoparticle can be used to treat cancer, for example, multiple myeloma.
Resumen de: MX2025005703A
Novel ionizable lipids are provided. Also provided are novel lipid nanoparticle compositions for the delivery of nucleic acid material to cells in vitro and in vivo with different and improved pharmacokinetic profiles as compared to what is typically observed in the art. Also provided are methods for using the compositions in research and as therapeutics.
Resumen de: AU2023382622A1
Lipid nanoparticles (LNPs) containing particular cationic ionizable lipids with a biologically active polynucleotides (e.g., RNAs) are provided. In some aspects, the LNP complexes are provided as aerosols and/or dry powders, such as for delivery to the lungs. Methods of making and using such compositions are provided.
Resumen de: MX2025005656A
The present invention refers to novel polyoxyalkylene based compounds and their manufacturing method as well as compositions comprising at least one novel polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.
Resumen de: EP4620460A1
The present invention relates to a nanoparticle composition for drug delivery and, more specifically, to a composition for drug delivery, wherein the composition comprises an amphiphilic block copolymer and a lipid with a specific structure that can easily form complexes with anionic drugs, whereby the composition can easily form drug-containing nanoparticles and thus is useful for drug delivery, especially for targeted delivery of drugs to the lungs.
Resumen de: AU2023379457A1
The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, polypeptides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain). Methods for treating various diseases or disorders, such as neurological diseases, with the conjugates are provided.
Nº publicación: EP4619417A1 24/09/2025
Solicitante:
UNIV AUT\u00D2NOMA DE BARCELONA [ES]
FUNDACIO INST DE RECERCA DE LHOSPITAL DE LA SANTA CREU I SANT PAU [ES]
Universitat Aut\u00F2noma de Barcelona,
Fundaci\u00F3 Institut de recerca de l'Hospital de la Santa Creu i Sant Pau
Resumen de: WO2024105116A1
The present invention relates to the field of nanostructured protein materials, more specifically to therapeutic agents carrying fusion proteins which can be used for therapy.
BOPI
Sede Electrónica
